

Title (en)  
NOVEL TYROSINE KINASE INHIBITORS

Title (de)  
NEUE TYROSINKINASEINHIBITOREN

Title (fr)  
NOUVEAUX INHIBITEURS DE LA TYROSINE KINASE

Publication  
**EP 1381598 A4 20080319 (EN)**

Application  
**EP 02723631 A 20020326**

Priority  
• US 0209402 W 20020326  
• US 27932701 P 20010328

Abstract (en)  
[origin: WO02079192A1] The present invention provides compounds of formula I[ ] and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

IPC 1-7  
**C07D 401/14; A61K 31/4184**

IPC 8 full level  
**A61K 31/4184** (2006.01); **A61K 31/443** (2006.01); **C07D 401/14** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/497** (2006.01); **A61K 31/506** (2006.01); **A61K 31/5377** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07D 401/04** (2006.01); **C07D 403/14** (2006.01); **C07D 405/14** (2006.01); **C07D 409/14** (2006.01); **C07D 413/14** (2006.01); **C07D 417/14** (2006.01); **C07D 521/00** (2006.01)

CPC (source: EP KR)  
**A61K 31/4184** (2013.01 - EP); **A61K 45/06** (2013.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07D 231/12** (2013.01 - EP); **C07D 233/56** (2013.01 - EP); **C07D 249/08** (2013.01 - EP); **C07D 401/04** (2013.01 - EP); **C07D 401/14** (2013.01 - EP KR); **C07D 409/14** (2013.01 - EP); **C07D 413/14** (2013.01 - EP); **C07D 417/14** (2013.01 - EP)

C-Set (source: EP)  
**A61K 31/4184 + A61K 2300/00**

Citation (search report)  
• [A] US 6162804 A 20001219 - BILODEAU MARK T [US], et al  
• [A] WO 0100610 A1 20010104 - AVENTIS PHARMA GMBH [DE]  
• [E] WO 2004031401 A2 20040415 - BRISTOL MYERS SQUIBB CO [US], et al  
• [PX] KATZ B A ET AL: "A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 307, no. 5, 13 April 2001 (2001-04-13), pages 1451 - 1486, XP004466071, ISSN: 0022-2836  
• See also references of WO 02079192A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)  
AL LT LV MK RO SI

DOCDB simple family (publication)  
**WO 02079192 A1 20021010**; AR 035804 A1 20040714; BG 108206 A 20041130; BR 0208373 A 20050222; CA 2442428 A1 20021010; CN 1514833 A 20040721; CZ 20032615 A3 20040317; EE 200300475 A 20040216; EP 1381598 A1 20040121; EP 1381598 A4 20080319; GE P20053660 B 20051110; HR P20030844 A2 20050831; HU P0400323 A2 20051128; IL 158041 A0 20040328; IS 6968 A 20030926; JP 2004534010 A 20041111; KR 20030083016 A 20031023; MX PA03008690 A 20031212; NO 20034308 D0 20030926; NO 20034308 L 20031126; PE 20021015 A1 20021110; PL 373300 A1 20050822; RU 2003131693 A 20050510; SK 12002003 A3 20041005; UY 27234 A1 20021031; YU 84603 A 20060303; ZA 200307466 B 20050113

DOCDB simple family (application)  
**US 0209402 W 20020326**; AR P020101167 A 20020327; BG 10820603 A 20030926; BR 0208373 A 20020326; CA 2442428 A 20020326; CN 02810516 A 20020326; CZ 20032615 A 20020326; EE P200300475 A 20020326; EP 02723631 A 20020326; GE AP2002005363 A 20020326; HR P20030844 A 20031017; HU P0400323 A 20020326; IL 15804102 A 20020326; IS 6968 A 20030926; JP 2002577817 A 20020326; KR 20037012594 A 20030926; MX PA03008690 A 20020326; NO 20034308 A 20030926; PE 2002000244 A 20020327; PL 37330002 A 20020326; RU 2003131693 A 20020326; SK 12002003 A 20020326; UY 27234 A 20020327; YU P84603 A 20020326; ZA 200307466 A 20030925